Overview

Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients

Status:
Recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
To compare the efficacy, as measured by time to treatment failure, of metronomic cyclophosphamide with respect to doxorubicin in elderly patients affected by mSTS.
Phase:
Phase 3
Details
Lead Sponsor:
Istituto Oncologico Veneto IRCCS
Collaborator:
Ministry of Health, Italy
Treatments:
Cyclophosphamide
Doxorubicin